Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kentaro Takeda

Showing results (21-30 of 64) with videos related to

Pageof 7
Sort By:
Clinical Pharmacology and Therapeutics|May 21, 2025
Dose Optimization in Oncology Drug Development: Risk Factors for Postmarketing Requirements and CommitmentsHiroe Kitagaki, Kentaro Takeda, Kazuya Murai, et al.
Pharmaceutical Statistics|October 17, 2025
BOIN-MEM: A Two-Stage Design for Dose Optimization With Information Borrowing Across Dose Levels and Stages in Oncology Phase I/II TrialsRyo Kitabayashi, Kentaro Takeda, Hiroyuki Sato, et al.
Journal of Biopharmaceutical Statistics|April 28, 2023
Optimal biological dose selection in dose-finding trials with model-assisted designs based on efficacy and toxicity: a simulation studyYusuke Yamaguchi, Kentaro Takeda, Satoshi Yoshida, et al.
Pharmaceutical Statistics|November 17, 2025
Statistical Consideration for Event-Free Survival With Cure Rate in Acute Myeloid Leukemia StudiesYuichiro Kaneko, Kentaro Takeda, Shufang Liu, et al.
Therapeutic Innovation & Regulatory Science|December 10, 2020
A Comparison Between a Meta-analytic Approach and Power Prior Approach to Using Historical Control Information in Clinical Trials With Binary EndpointsNaoki Isogawa, Kentaro Takeda, Kazushi Maruo, et al.
Cancer Reports (Hoboken, N.J.)|January 17, 2021
Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancerHideki Maeda, Kentaro Takeda, Hisashi Urushihara, et al.
Therapeutic Innovation & Regulatory Science|August 2, 2019
A Comparison Between a Meta-analytic Approach and Power Prior Approach to Using Historical Control Information in Clinical Trials With Binary EndpointsNaoki Isogawa, Kentaro Takeda, Kazushi Maruo, et al.
Journal of Biopharmaceutical Statistics|February 19, 2024
A basket trial design based on constrained hierarchical Bayesian model for latent subgroupsKentaro Takeda, Atsuki Hashimoto, Shufang Liu, et al.
Biometrical Journal. Biometrische Zeitschrift|June 13, 2023
TITE-gBOIN-ET: Time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomesKentaro Takeda, Yusuke Yamaguchi, Masataka Taguri, et al.
Pharmaceutical Statistics|August 6, 2023
A Bayesian optimal interval design for dose optimization with a randomization scheme based on pharmacokinetics outcomes in oncologyKentaro Takeda, Jing Zhu, Ran Li, et al.
Pageof 7

Showing results (21-30 of 64) with videos related to

Sort By:
Pageof 7
Clinical Pharmacology and Therapeutics|May 21, 2025
Dose Optimization in Oncology Drug Development: Risk Factors for Postmarketing Requirements and CommitmentsHiroe Kitagaki, Kentaro Takeda, Kazuya Murai, et al.
Pharmaceutical Statistics|October 17, 2025
BOIN-MEM: A Two-Stage Design for Dose Optimization With Information Borrowing Across Dose Levels and Stages in Oncology Phase I/II TrialsRyo Kitabayashi, Kentaro Takeda, Hiroyuki Sato, et al.
Journal of Biopharmaceutical Statistics|April 28, 2023
Optimal biological dose selection in dose-finding trials with model-assisted designs based on efficacy and toxicity: a simulation studyYusuke Yamaguchi, Kentaro Takeda, Satoshi Yoshida, et al.
Pharmaceutical Statistics|November 17, 2025
Statistical Consideration for Event-Free Survival With Cure Rate in Acute Myeloid Leukemia StudiesYuichiro Kaneko, Kentaro Takeda, Shufang Liu, et al.
Therapeutic Innovation & Regulatory Science|December 10, 2020
A Comparison Between a Meta-analytic Approach and Power Prior Approach to Using Historical Control Information in Clinical Trials With Binary EndpointsNaoki Isogawa, Kentaro Takeda, Kazushi Maruo, et al.
Cancer Reports (Hoboken, N.J.)|January 17, 2021
Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancerHideki Maeda, Kentaro Takeda, Hisashi Urushihara, et al.
Therapeutic Innovation & Regulatory Science|August 2, 2019
A Comparison Between a Meta-analytic Approach and Power Prior Approach to Using Historical Control Information in Clinical Trials With Binary EndpointsNaoki Isogawa, Kentaro Takeda, Kazushi Maruo, et al.
Journal of Biopharmaceutical Statistics|February 19, 2024
A basket trial design based on constrained hierarchical Bayesian model for latent subgroupsKentaro Takeda, Atsuki Hashimoto, Shufang Liu, et al.
Biometrical Journal. Biometrische Zeitschrift|June 13, 2023
TITE-gBOIN-ET: Time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomesKentaro Takeda, Yusuke Yamaguchi, Masataka Taguri, et al.
Pharmaceutical Statistics|August 6, 2023
A Bayesian optimal interval design for dose optimization with a randomization scheme based on pharmacokinetics outcomes in oncologyKentaro Takeda, Jing Zhu, Ran Li, et al.
Pageof 7